GNH USA

Europe — EMA

Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

GNH USA supplies Irinotecan Kabi (Irinotecan), a camptothecin analog for metastatic colorectal cancer and small cell lung cancer. Request a quote.

Irinotecan Hydrochloride Trihydrate

Request sourcing

1
Pack/s

What is Irinotecan Hydrochloride Trihydrate?

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a camptothecin analog presented as a sterile powder for intravenous use. It is employed in the treatment of metastatic colorectal cancer and small cell lung cancer in adult patients, and is indicated for those who have progressed after standard therapies.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable cold‑chain logistics where required.

What is Irinotecan Hydrochloride Trihydrate used for?

Irinotecan Kabi is a topoisomerase I inhibitor used in oncology for specific solid tumours.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens. Small cell lung cancer: used as part of combination chemotherapy for extensive‑stage disease.

What are the side effects of Irinotecan Hydrochloride Trihydrate?

Irinotecan Kabi may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting - Diarrhoea - Neutropenia - Fatigue - Alopecia - Anorexia

Serious or Rare Side Effects: - Febrile neutropenia - Severe diarrhoea or colitis - Hepatic toxicity (elevated transaminases) - Severe allergic reactions (anaphylaxis) - Secondary malignancies - Life‑threatening infections

What precautions apply to Irinotecan Hydrochloride Trihydrate?

Before initiating therapy, clinicians should evaluate patient suitability and monitor for toxicity.

Baseline blood counts: assess neutrophil and platelet levels. Liver function: monitor transaminases and bilirubin. Bowel obstruction risk: evaluate for pre‑existing gastrointestinal issues. Dose adjustment: consider hepatic impairment when dosing. Hypersensitivity: avoid in patients with known allergy to irinotecan or formulation components. Store at ambient temperature: keep in original container, protect from moisture and light.

What does Irinotecan Hydrochloride Trihydrate interact with?

Irinotecan may interact with other medicines; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) - UGT1A1 inhibitors (e.g., atazanavir) - Concurrent myelosuppressive chemotherapy agents - High‑dose radiation therapy to the abdomen

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) - Anticoagulants (may increase bleeding risk) - Diuretics (potential electrolyte disturbances)

Frequently asked questions

What is Irinotecan Kabi used for?+
Irinotecan Kabi is an intravenous antineoplastic agent indicated for the treatment of metastatic colorectal cancer and extensive‑stage small cell lung cancer in adult patients, typically as part of combination chemotherapy regimens.
How does Irinotecan work?+
After administration, Irinotecan is metabolised to SN‑38, which inhibits topoisomerase I. This prevents the re‑ligation of single‑strand DNA breaks, leading to accumulation of DNA damage, interruption of replication and transcription, and ultimately tumour cell death.
What is the usual dose of Irinotecan Kabi?+
The dose of Irinotecan Kabi is determined by the prescribing oncologist based on the patient’s body surface area, disease stage, prior therapies and organ function. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.
Is Irinotecan Kabi safe in pregnancy or breastfeeding?+
Safety data for Irinotecan Kabi in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.
How do I order Irinotecan Kabi from GNH USA?+
To place an order, submit an enquiry on the Irinotecan Kabi product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.
How does Irinotecan Kabi compare with other topoisomerase I inhibitors?+
Irinotecan and topotecan are both topoisomerase I inhibitors, but Irinotecan is commonly used for colorectal and small cell lung cancers, whereas topotecan is approved mainly for ovarian and small cell lung cancers. Differences include dosing schedules, metabolic pathways (SN‑38 for Irinotecan) and specific toxicity profiles.
What are the storage and handling requirements for Irinotecan Kabi?+
Irinotecan Kabi should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, light and physical shock. Reconstitute and use according to the supplied instructions, and discard any unused portion after the recommended time.
How is Irinotecan Kabi administered?+
Irinotecan Kabi is given by intravenous infusion, usually over 30 to 90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified healthcare professionals, with appropriate monitoring for infusion‑related reactions.
What are the most serious risks to watch for while on Irinotecan Kabi?+
The most serious adverse events include severe neutropenia or febrile neutropenia, life‑threatening diarrhoea or colitis, hepatic toxicity, and rare but severe allergic reactions. Prompt medical attention is required if patients develop fever, persistent diarrhoea, jaundice or signs of anaphylaxis.
Who should not use Irinotecan Kabi?+
Irinotecan Kabi is contraindicated in patients with known hypersensitivity to irinotecan or any excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment that precludes dose adjustment. Clinicians should also avoid use in patients with recent bowel obstruction.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Irinotecan Hydrochloride Trihydrate
Route
Intravenous Use
Manufacturer
Fresenius Kabi Italia S.R.L.
Origin
EU

Related products

Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer S.A.
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Holding France
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Hellas A.E.
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Healthcare Ireland Unlimited Company
EU